The Nasdaq and S&P 500 worked to recover some of Monday's steep losses
Stocks managed to regain some traction ahead of tomorrow's conclusion of the Federal Reserve's two-day policy meeting, in which the CME FedWatch tool has pointed to a high probability of unchanged interest rates. The Dow eked out another healthy win, while the Nasdaq and S&P 500 worked to recover a large portion of yesterday's steep AI-triggered losses, which sent the pair to their worst daily drops since mid-December.
Continue reading for more on today's market, including:
- Pharma giant gearing up for earnings.
- Analyst upgrade triggers call trader frenzy.
- Plus, travel stocks seeing post-earnings buzz; another grim Boeing update; and the gold stock to watch right now.
5 Things to Know Today
- Trillions of dollars worth of federal funding programs are at risk as the Trump Administration hits pause to look at whether they match the president's "policies and requirements." (MarketWatch)
- The U.S. Food and Drug Administration (FDA) has approved the use of weight-loss drug Ozempic for the treatment of kidney disease and diabetes. (CNBC)
- Post-earnings buzz for these two travel stocks.
- New Boeing plan looks to find a light in the perpetual dark.
- Gold stock riding the broader-market rebound.
Oil, Gold Recover From Tech-Triggered Pullback
Crude futures finished in the black Tuesday, riding on the post-selloff recovery out of the tech sector. March-dated West Texas Intermediate (WTI) crude climbed 26 cents, or 0.3%, to settle at $73.43 per barrel.
Tariff buzz and recovering tech pushed gold higher for the session. The contract for February delivery added 1.3% to settle at $2,772,60 an ounce.